Advisory Resource Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisory Resource Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81M	Buy	3,638 +111	+3%	+$49.2K	0.27%	94
2026 Q1	$1.57M	Sell	3,527 -92	-3%	-$42.9K	0.27%	77
2025 Q4	$1.64M	Buy	3,619 +335	+10%	+$144K	0.29%	74
2025 Q3	$1.29M	Buy	+3,284	New	+$1.37M	0.23%	102
2025 Q1	–	Sell	-2,461	Closed	-$991K	–	166
2024 Q4	$991K	Buy	2,461 +491	+25%	+$228K	0.21%	108
2024 Q3	$916K	Buy	1,970 +61	+3%	+$29.3K	0.2%	107
2024 Q2	$895K	Buy	+1,909	New	+$829K	0.2%	100

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Advisory Resource Group's VRTX Position: Q2 2026 in Review

Advisory Resource Group increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q2 2026, buying an estimated $49.2K and bringing the position to 3,638 shares worth $1.81M. The position accounts for 0.27% of the portfolio, ranked #94.

Advisory Resource Group first reported a position in VRTX in Q2 2024 and has held it in 7 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Advisory Resource Group held 3,638 shares of Vertex Pharmaceuticals worth $1.81M as of Q2 2026.
Advisory Resource Group bought 111 Vertex Pharmaceuticals shares in Q2 2026, an estimated $49.2K.
Vertex Pharmaceuticals made up 0.27% of Advisory Resource Group's portfolio in Q2 2026, its #94 holding.
Advisory Resource Group first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Advisory Resource Group's 13F filing for Q2 2026, filed 14 Jul 2026.